This site is intended for health professionals only
Tuesday 26 March 2019
Share |

Topic: Cardiovascular

March 15, 2019
Rod Tucker on what pharmacists should tell patients interested in high intensity exercises

The NHS has described exercise as a miracle cure that is able to reduce the risk of major illnesses such as heart disease, stroke, Type 2 diabetes and even cancer.
 

March 4, 2019
Substantial data have been published since the last Scientific Statement in 2005 showing the importance of measuring blood pressure outside of the clinic setting
The accurate measurement of blood pressure is essential for the diagnosis and management of hypertension, a major risk factor for heart disease and stroke, according to an updated American Heart Association scientific statement on blood pressure measurement in humans, published in the American Heart Association journal Hypertension.
 
March 4, 2019
Randomised clinical trial demonstrates safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only
Two-year data from the RM-ALONE Trial1 evaluating the safety and workflow efficiency of remote cardiac monitoring with remote interrogations were recently published in the European Heart Journal.
 
The authors analysed the efficacy of Biotronik Home Monitoring® as a follow-up method after the implantation of cardiac implantable electronic devices (CIEDs) without regular in-person evaluations with a physician. 
 
December 11, 2018
The study was a retrospective analysis of all patients with acute ST-segment elevation myocardial infarction treated at Triemli Hospital in Switzerland between 2000 and 2016

Women are being urged to call an ambulance immediately if they have heart attack symptoms, following research showing they wait longer than men to get help. The study has been published in European Heart Journal: Acute Cardiovascular Care, a publication of the European Society of Cardiology (ESC).1

November 29, 2018
Researchers investigated cardiac function in relation to diagnosed OSA and self-reported snoring from data available through UK Biobank

Obstructive sleep apnoea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men, according to a new study presented at the annual meeting of the Radiological Society of North America.

Moreover, the findings suggested that OSA may be vastly underdiagnosed among snorers.

November 9, 2018

NHS England spends over £1bn per year on diabetes prescriptions, data has revealed.
 
A report published yesterday (8 November) by NHS Digital showed that the cost of prescriptions for diabetes has grown by £422m in a decade, reaching more than £1bn in 2017/18.
 

October 30, 2018
Interviews were conducted to characterise two healthcare practitioners’ adoption of peripherally inserted central catheters into their clinical practices and the resulting clinical and economic benefits associated with their use

Disclaimer

This case study reflects the individual experiences of two healthcare practitioners and does not represent a scientific study or present clinical evidence. Results for other clinicians or institutions will vary. Please consult manufacturer’s instructions for use for relevant warnings, indications, and counterindications.
 

Disclosure

October 24, 2018

An implanted cardiac defibrillator (ICD) can effectively put a stop to any underlying cardiac arrhythmia, a study has found [24 October 2018].
 
In a long-term observational study involving 1,500 patients, researchers from MedUni Vienna's Department of Medicine II (division of cardiology) have shown that the programming selected for the implanted defibrillators (ICDs) plays a major role.
 
It was found that the most "defensive" possible procedure was safe and, at the same time, significantly reduced inappropriate therapy.

October 24, 2018

Global biotechnology company Amgen’s Repatha® (evolocumab) has been selected as a Rapid Uptake Product by the Accelerated Access Collaborative (AAC), the Department of Health and Social Care (DHSC) has announced [October 23 2018].
 

October 11, 2018

A one-off DNA test could spot people at risk of a heart attack in adulthood much earlier in life for just £40, according to new research.
 
The study, part-funded by the charity the British Heart Foundation and published in the Journal of the American College of Cardiology, developed a new scoring system to identify those at risk because of their genetics.
 
It costs £40, making it a “cost effective” way of helping preventing heart disease according to the report’s authors.
 

October 11, 2018

A one-off DNA test could spot people at risk of a heart attack in adulthood much earlier in life for just £40, according to new research.
 
The study, part-funded by the charity the British Heart Foundation and published in the Journal of the American College of Cardiology, developed a new scoring system to identify those at risk because of their genetics.
 
It costs £40, making it a “cost effective” way of helping preventing heart disease according to the report’s authors.
 

October 8, 2018
Mechanical thrombectomy using state of the art devices has revolutionised the treatment of patients with severe disabling strokes due to large vessel occlusion with proven efficacy in re-establishing intracranial circulation and improving patient outcomes
Stroke is the second single most common cause of death in the world, with 6.7 million stroke-related deaths each year.1 The burden of disease (disability, illness and premature deaths) caused by stroke is set to double worldwide by 2030.1 Stroke affects 152,000 people annually in the UK; that is 1 person every 3 minutes 27 seconds.2 Large vessel occlusion often causes severe strokes and is associated with high mortality, morbidity, poor clinical outcomes and high societal costs.3
 
September 11, 2018
With new candidates identified from different pathophysiological pathways, new technologies for measurement and more perspectives of data integration, the transformation is ongoing in the field of cardiac biomarkers
September 11, 2018
The development of PCSK9 inhibitors is a great example of serendipity, clever exploitation of a fascinating genetic observation, and rational drug development using monoclonal antibody technology in the 21st century
September 11, 2018
Patients with chronic kidney disease have an elevated risk for bleeding with declining glomerular filtration rate, even in the absence of anticoagulants, but also have an elevated risk of thromboembolism
Chronic kidney disease (CKD), a reduction in renal function with decreasing glomerular filtration rate (GFR) is increasing in incidence as well as in prevalence due to a growing elderly population. The progressive reduction in GFR to less than 60ml/min (modest renal insufficiency; mRI) or severe renal insufficiency (sRI; with GFR <30ml/min) may lead to end stage renal disease (ESRD) with a requirement for chronic haemodialysis (CHD).
 
September 11, 2018
From the breakthroughs of early pioneers to the present day, the quest to improve outcomes and reduce complications goes on
June 20, 2018
Idorsia launches PRECISION – Phase 3 study with aprocitentan for resistant hypertension management in adults

Swiss biopharmaceuticals business Idorsia has announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for managing resistant hypertension in adults [June 20 2018].
 

June 9, 2018
Preview of the 2018 European Society of Cardiology and European Society of Hypertension Joint Guidelines for the Management of Arterial Hypertension

A first look at the new European Guidelines for the treatment of high blood pressure was presented at the European Society of Hypertension meeting in Barcelona on 9 June 2018.

May 28, 2018
This study investigated the reasons why just 21% of patients enrolled in the PARADIGM-HF trial were women

Clinical trial enrolment favours men, according to a study presented at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology congress.

May 26, 2018
REPORT-HF is a global, prospective registry comparing regional differences in causes of acute heart failure, therapies, time to treatment, and outcomes

Triggers of acute heart failure vary globally, according to late breaking results from the REPORT-HF registry presented today at Heart Failure 2018 and the World Congress on Acute Heart Failure, a European Society of Cardiology congress.1

May 25, 2018
First patient in Scotland to be fitted with a CardioMEMS device

In a Scottish first, specialists at the Golden Jubilee National Hospital have implanted a new device which remotely monitors heart failure patients as part of the COAST clinical trial.

The study will see up to 10 patients receive cardioMEMS implants over two years with the aim of proving the device is cost-effective to use widely throughout NHS in the UK.

May 22, 2018
GDE Trust of the year Royal Liverpool and Broadgreen University Hospitals NHS Trust working with UK-based artificial intelligence health company, Deontics, to enhance clinical decision making and reduce risk of heart attack

Global Digital Exemplar, Royal Liverpool and Broadgreen University Hospitals NHS Trust is using artificial intelligence (AI) to improve the treatment of patients who have had a heart attack, in a project that could see wider use of AI to inform treatment decisions across the Trust.

May 21, 2018
The study analysed data from more than 421,000 people aged 60–69 in both GP medical records and in the UK Biobank research study. Participants were followed up over ten years.

New research has shown that older people with very low heart disease risks also have very little frailty, raising the possibility that frailty could be prevented.

The largest study of its kind, led by the University of Exeter, found that even small reductions in risk factors helped to reduce frailty, as well as dementia, chronic pain, and other disabling conditions of old age.

May 17, 2018
New indication supports Amgen’s commitment to reduce the risk of recurrent cardiovascular events faced by heart attack and stroke survivors

Amgen has announced announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels.